• Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial 

      Østergaard, Mikkel; Van Vollenhoven, Ronald F; Rudin, Anna; Hetland, Merete Lund; Schrumpf, Marte; Nordström, Dan C; Nurmohamed, Michael T; Gudbjornsson, Bjorn; Ørnbjerg, Lykke Midtbøll; Bøyesen, Pernille; Lend, Kristina; Hørslev-Petersen, Kim; Uhlig, Till; Sokka, Tuulikki; Grondal, Gerdur; Krabbe, Simon; Lindqvist, Joakim; Gjertsson, Inger; Glinatsi, Daniel; Kapetanovic, Meliha Crnkic; Aga, Anna-Birgitte; Faustini, Francesca; Parmanne, Pinja; Lorenzen, Tove; Giovanni, Cagnotto; Back, Johan; Hendricks, Oliver; Vedder, Daisy; Rannio, Tuomas; Grenholm, Emma; Ljoså, Maud-Kristine Aga; Brodin, Eli; Lindegaard, Hanne; Söderbergh, Annika; Rizk, Milad; Kastbom, Alf; Larsson, Per; Uhrenholt, Line; Just, Søren Andreas; Stevens, David John; Bay Laurbjerg, Trine; Bakland, Gunnstein; Olsen, Inge Christoffer; Haavardsholm, Espen A.; Lampa, Jon (Peer reviewed; Journal article, 2023)
      Background - The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with ...